Bayer's (BAYRY) AskBio Advances Parkinson Disease Study

In the past 30 days, the Zacks Consensus Estimate for Annovis' 2024 loss per share has remained constant at $2.46. During the same period, the consensus estimate for 2025 loss per share has remained constant at $1.95. ANVS beat on earnings in three of the trailing four quarters and missed once, delivering an average negative surprise of 1.39%. REGENERATE-PD is a phase II study evaluating the efficacy and safety of AB-1005, an investigational adenoassociated virus 2 (AAV2) glial cell line-derived neurotrophi ...